Use of gonadotrophin releasing hormone (GnRH) antagonist (cetrotide) during ovarian stimulation for in-vitro fertilization treatment: multiple doses and single dose

J Obstet Gynaecol Res. 2001 Oct;27(5):261-5. doi: 10.1111/j.1447-0756.2001.tb01267.x.

Abstract

Objectives: To report preliminary experience in using the GnRH antagonist (Cetrotide) and to compare the multiple dose and single dose protocols.

Methods: Fifteen patients received multiple doses and another 10 patients received the single dose protocol of GnRH antagonist during ovarian stimulation for IVF treatment. Outcome measures included the duration/dosage of gonadotrophin and number of oocytes aspirated.

Results: All patients had successful oocyte retrieval after the hCG injection. The single dose group had a significantly shorter duration of gonadotrophin but fewer frozen embryos than the multiple dose group.

Conclusions: Both protocols were effective in preventing premature LH surges. The stimulation regimen was simplified by reducing the total treatment period, the dosage and duration of gonadotrophin. There may be differences in ovarian responses between the two protocols.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Embryo Transfer
  • Female
  • Fertilization in Vitro*
  • Gonadotropin-Releasing Hormone / administration & dosage*
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Hormone Antagonists / administration & dosage*
  • Humans
  • Luteinizing Hormone / blood
  • Ovarian Hyperstimulation Syndrome / prevention & control*

Substances

  • Hormone Antagonists
  • Gonadotropin-Releasing Hormone
  • Luteinizing Hormone
  • cetrorelix